- Munich Re’s preliminary Q2 2025 profit is approximately €2.1 billion, surpassing the estimated €1.71 billion.
- The company maintains its full-year profit forecast of €6 billion, compared to the market estimate of €6.06 billion.
- Final Q2 2025 results will be released on 8 August 2025.
- Strong operational performance in property-casualty reinsurance contributed positively, with low major-loss expenses in this area.
- Life and health reinsurance results were negatively impacted by an accumulation of significant individual losses.
- Currency fluctuations, particularly the depreciation of the US dollar, had a negative effect on the group’s financial results.
- Analyst recommendations for Munich Re stocks include 6 buys, 11 holds, and 5 sells.
A look at Muenchener Rueckversicherungs- Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 4 | |
| Growth | 5 | |
| Resilience | 4 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 4.0 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Based on Smartkarma Smart Scores, Muenchener Rueckversicherungs-Gesellschaft AG (MunichRe) shows a promising long-term outlook. With a high Growth score of 5, the company is positioned well for expansion and increased profitability in the future. Additionally, scoring 4 in both Dividend and Resilience factors indicates a stable financial performance with attractive dividend payouts for investors.
MunichRe’s overall outlook is further bolstered by its strong Momentum score of 4, reflecting positive market sentiment and potential for continued upward movement. While scoring 3 in Value, the company still presents a reasonably favorable valuation proposition. With a widespread presence and a diverse range of services including reinsurance, insurance, and asset management, MunichRe remains a key player in the financial services sector across global markets.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
